---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-070355"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2022-06-13T23:59:59+00:00"
generated_at: "2026-06-25T02:15:14.330152+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Onconova promotes Guerin to COO/CFO, Makovski Silverstein to head corp dev; Oler resigns

## Summary
- Mark Guerin appointed COO/CFO; salary raised to $475K; receives 50,250 options and 16,500 RSUs.
- Dr. Adar Makovski Silverstein promoted to Senior Director and Head of Corporate Development.
- Avi Oler, SVP Corporate Development and General Counsel, resigns effective June 17, 2022.
- Guerin's equity awards vest over three years: RSUs 33/33/34%, options 1/3 at year 1 then monthly.

## SEC filing metadata
- accession: 0001104659-22-070355
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2022-06-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465922070355/0001104659-22-070355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465922070355/tm2218255d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-070355
- JSON: https://secwatch.observer/filing/0001104659-22-070355.json
- Plain text: https://secwatch.observer/filing/0001104659-22-070355.txt

## Key facts
- Executive change
  Abraham N. Oler resigned as Senior Vice President, Corporate Development and General Counsel at Traws Pharma, Inc..
  - Action: resigned
  - Role: Senior Vice President, Corporate Development and General Counsel
  source text: On June 10, 2022, Abraham N. Oler, Senior Vice President, Corporate Development and General Counsel, notified the company of his resignation effective June 17, 2022 to pursue an opportunity outside the biotechnology sector.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130598/000110465922070355/0001104659-22-070355-index.htm
- Executive change
  Mark Guerin was appointed as Chief Operating Officer at Traws Pharma, Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On June 10, 2022, Onconova Therapeutics, Inc. (the “Company”) appointed Mark Guerin, as Chief Operating Officer in addition to his current role as Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130598/000110465922070355/0001104659-22-070355-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.